Sign in
Not yet taking people in EgyptNo phase

Botulinum Toxin and Nerve Block Tested Together for Chronic Migraine

Tests botulinum toxin with a nerve block in adults with chronic migraine headaches.

Key facts

Who runs it
Beni-Suef University
Where
Al Fayyum, EgyptSee the site
Trial code
Registry title
Botulinum Toxin and/or Greater Occipital Nerve Block for Patients With Chronic Migraine
Status
Not yet recruiting
People taking part
90 people, planned
Started
Apr 2026
Expected to end
Dec 2026
Type of study
Interventional, 3 groups
Treatments tested
  • OnabotulinumtoxinA
  • Greater Occipital Nerve Block (GONB)
Record updated
17 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic migraine. It tests botulinum toxin (OnabotulinumtoxinA) injections together with a greater occipital nerve block, compared with a single treatment.

Age
Older than 18 years
Sex
Women and men can join
Disease stage
Chronic migraine: headache on 15 or more days per month for more than three months, with at least 8 days per month showing migraine features
Earlier treatment
Must have been on a stable migraine preventive treatment for at least two months. Cannot have had BoNT-A or a greater occipital nerve block for headache in the previous 3 months.

Main reasons for not taking part

  • Known allergy to BoNT-A or local anesthetics
  • Neck anatomy problems that make the injections hard or unsafe
  • Neuromuscular junction disorders such as myasthenia gravis
  • Bleeding disorders or blood thinner treatment that rules out a nerve block
  • Pregnancy

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Diagnosis of chronic migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3): headache occurring on ≥15 days per month for more than three months, with at least 8 days per month exhibiting migraine features. (International Headache Society, 2013)
  • Age > 18 years
  • Stable preventive migraine regimen for at least two months prior to recruitment

Who cannot take part

  • Prior treatment with BoNT-A or GONB for headache within the previous 3 months
  • Known hypersensitivity to BoNT-A or local anesthetics
  • Neuromuscular junction disorders (e.g., myasthenia gravis)
  • Coagulation disorders or anticoagulant therapy that contraindicates nerve block
  • Significant psychiatric comorbidity that would impair proper pre and post treatment assessment
  • Co-morbid other
  • Cervical anatomical abnormalities that hinder proper localization of injection sites or compromise the safety of the procedure
  • Pregnancy

Where in Egypt

  • Beni-Suef University HospitalAl Fayyum, EgyptContact: Rakia Mohamed Basiouny, neurology residentNot yet recruiting

About the trial

What the trial wants to find out

Chronic migraine is a debilitating neurological disorder that significantly affects patients' daily functioning, mental health, and quality of life. Management typically includes acute and preventive treatments, but effectiveness can be limited due to medication overuse or delayed onset of action. OnabotulinumtoxinA injections provide proven long-term preventive benefits, while Greater Occipital Nerve (GON) block offers rapid but short-term relief. Although both treatments are used individually, evidence on the combined effect is limited. This randomized controlled trial aims to evaluate the efficacy and safety of combining OnabotulinumtoxinA injections with GON block, assessing improvements in headache frequency, severity, and patient quality of life compared to single therapy.

The 3 groups in the trial

  • Arm 1: BoNT-A + GONBTreatment being tested

    Treatment: OnabotulinumtoxinA and Greater Occipital Nerve Block (GONB)

  • Arm 2: BoNT-A aloneTreatment being tested

    OnabotulinumtoxinA will be injected intramuscularly at standard PREEMPT injection sites for chronic migraine prophylaxis. Total dose per session: 155 units distributed across 31 sites.

    Treatment: OnabotulinumtoxinA

  • Arm 3: GONB aloneTreatment being tested

    Injection of local anesthetic (2% lidocaine, 1-2 mL per side) around the greater occipital nerve at the occipital region. Procedure performed by trained neurologist.

    Treatment: Greater Occipital Nerve Block (GONB)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Botulinum Toxin and/or Greater Occipital Nerve Block for Patients With Chronic Migraine
Plain-language title
Botulinum Toxin and Nerve Block Tested Together for Chronic MigraineGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
17 April 2026